Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 2,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: High Intensity Interval Exercise, Moderate Intensity Continuous Exercise, Control; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 51 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions: Risk Reduction; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40,671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Venothromboembolism
Interventions: Risk model-driven CDS; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Not listed
Enrollment: 2,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: LFF269, Eplerenone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 11
States / cities: Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more

Conditions: HIV Infections
Interventions: Interleukin-2 SA, HAART; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 9
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more

Conditions: Suicidal Ideation, Treatment Engagement
Interventions: MI-SI+TAU, MI-SI-R+TAU, TAU Alone; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions: Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Robbinsdale, Minnesota

Conditions: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 36
States / cities: Bakersfield, California • Fresno, California • Los Angeles, California + 27 more

Conditions: Type 2 Diabetes
Interventions: Placebo, Survodutide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 65 more

Conditions: Traumatic Brain Injury, Word Finding Difficulty, Acquired Brain Injury, Cognitive Change
Interventions: Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: AIDS-Related-Primary Central Nervous System Lymphoma
Interventions: Methotrexate, Rituximab, Leucovorin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Food Allergy
Interventions: Low dose ADP101, High dose ADP101, Pooled Placebo; Biological
Lead sponsor: Alladapt Immunotherapeutics, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more

Conditions: Bipolar Disorder, Schizo Affective Disorder
Interventions: High-Definition Transcranial Electrical-Current Stimulation, High-Definition Transcranial Alternate-Current Stimulation, High-Definition Personalized Beta-Gamma Electrical Stimulation; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Anxiety Sensitivity, Eating, Physical Activity
Interventions: Anxiety Sensitivity Training, Health Control; Other
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head Cancer, Neck Cancer, Pain
Interventions: Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: Jennifer E. Lee; Other
Eligibility: 18 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Stroke, High Intensity Interval Exercise
Interventions: Single, acute bout of high intensity interval exercise; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Brain Care Score, Exercise, Hypertension, BMI
Interventions: Exercise Intervention to improve overall Brain Health; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 35 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Obesity
Interventions: Moderate intensity weight loss, High intensity medical weight loss; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: quality of life questionnaires; Behavioral
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 65 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 13
States / cities: Elkhart, Indiana • Kokomo, Indiana • La Porte, Indiana + 6 more

Conditions: Physical Fitness
Interventions: The First Twenty, Comparison; Behavioral
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Uveitis; Posterior, Disorder
Interventions: DE-109 44 ug, DE-109 440 ug, DE-109 880 ug; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 74
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 71 more

Conditions: Norovirus Gastroenteritis
Interventions: VXA-G1.1-NN Oral Vaccine; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hepatitis B
Interventions: INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment; Biological · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Manhasset, New York + 4 more

Conditions: Prostate Cancer
Interventions: Lower-Carbohydrate Med-t-Diet, Low-Fat Med-t-Diet; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes

Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications

AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

Motivational Interviewing to Prevent Suicide in High Risk Veterans

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Treating Civilian Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation (ciTBI-HDtDCS)

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Causal Lesion Network Guided Treatment of Bipolar Mania With Transcranial Electrical Stimulation

Computer-Delivered Intervention for Individuals With Obesity and Elevated Anxiety Sensitivity

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

Blood Flow Response and Acute INterval Exercise

An Exercise Intervention to Improve Overall Brain Health

Impact of Weight Loss on Physical Function

Assessing Older Patients With Cancer

The First 20 Fire Academy Recruits Exercise Training Program

Study Assessing Double-masked Uveitis Treatment

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer